Chris Riback's Newsletter

Chris Riback's Newsletter

'First Public Comments'

What You Need To Know

Jun 27, 2023
∙ Paid

Today’s posts that caught my eye:

  1. The battle to provide obesity treatments jumped to a new level on Monday, with Eli Lilly announcing that an experimental drug that acts on three hormones (rather than the single target in Novo Nordisk’s Wegovy) led to the greatest weight loss yet seen by a new generation of drugs. The weekly injectable, called retatruti…

User's avatar

Continue reading this post for free, courtesy of Chris Riback.

Or purchase a paid subscription.
© 2026 Chris Riback · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture